Skip to main content
SpringerLink
Log in

Imaging in Gastrointestinal Cancer

  • Chapter
  • First Online:
Gastrointestinal Oncology

  • 1671 Accesses

Abstract

Routine and innovative imaging approaches are used for screening, diagnosis and staging, monitoring treatment, and surveillance in gastrointestinal cancers. While screening endoscopy has been the standard for diagnosing most gastrointestinal tumors, noninvasive CT colonography has evolved and is beginning to find routine use in practice. For diagnosis and staging, the CT scan has been the backbone of imaging over the last 30 years. Functional imaging modalities, such as PET scans, are now employed as an added tool to assist in the diagnosis and staging of GI cancers, particularly to detect occult metastatic disease so futile surgical interventions can be avoided. PET has been adopted for routine staging for esophageal cancers and data is evolving in other GI cancers. Clinical trials data using functional imaging for early treatment monitoring for GI cancers is limited. The best data is in esophageal cancer, where a multi-institutional study showed that PET done at 2 weeks after induction chemotherapy could be used to identify patients with metabolic response. Future clinical trials using functional imaging may enable clinicians to provide rapid adjustments to therapy for each patient. The role of surveillance in patients with resected cancer is to detect early recurrence, which is amenable to curative resections. Studies have shown that routine follow-up with CT, along with CEA and colonoscopy has shown to improve survival in colorectal cancer patients. Ultimately, the proper use of all available imaging technology will translate to improved clinical outcomes in GI cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • van den Abbeele AD for the GIST Collaborative PET Study Group (Dana-Farber Cancer Institute, OHSU, Helsinki University Central Hospital, Turku University Central Hospital, Novartis Oncology (2001) F18-FDG-PET provides early evidence of biological response to STI571 in patients with malignant gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol 20:362

    Google Scholar 

  • Aloj L, Caraco C, Jagoda E, Eckelman WC, Neumann RD (1999) Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res 59:4709–4714

    CAS  PubMed  Google Scholar 

  • Amthauer H, Denecke T, Rau B, Hildebrandt B, Hunerbein M, Ruf J, Schneider U, Gutberlet M, Schlag PM, Felix R, Wust P (2004) Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology. Eur J Nucl Med Mol Imaging 31:811–819

    Article  PubMed  Google Scholar 

  • Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, Bockisch A, Debatin JF, Freudenberg LS (2004) Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 45:357–365

    CAS  PubMed  Google Scholar 

  • Arnold D, Hinke A, Reinacher-Schick AC, Schmiegel W, Graeven U, Kubicka S, Weikersthal LF, Moosmann N, Schmoll H, Heinenam V (2008) Waterfall plot analysis of XELOX or XELIRI with cetuximab or bevacizumab in patients with advanced colorectal cancer (ACRC): combined analysis of two randomized first-line phase II trials of the AIO CRC study group. 2008 ASCO annual meeting. J Clin Oncol 26: (May 20 suppl; abstr 4067)

    Google Scholar 

  • Avril NE, Weber WA (2005) Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am 43:189–204

    Article  PubMed  Google Scholar 

  • Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, Werner M, Graeff H, Schwaiger M, Kuhn W (2005) Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 23:7445–7453

    Article  PubMed  Google Scholar 

  • Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Charnsangavej C (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25:1760–1764

    Article  PubMed  Google Scholar 

  • Blue Cross Blue Shield (2000) FDG PET Positron Emission Tomography in Pancreas [Brochure]. Chicago

    Google Scholar 

  • Bombardieri E, Aliberti G, de Graaf C, Pauwels E, Crippa F (2001) Positron emission tomography (PET) and other nuclear medicine modalities in staging gastrointestinal cancer. Semin Surg Oncol 20:134–146

    Article  CAS  PubMed  Google Scholar 

  • Calvo FA, Domper M, Matute R, Martinez-Lazaro R, Arranz JA, Desco M, Alvarez E, Carreras JL (2004) 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 58:528–535

    Article  PubMed  Google Scholar 

  • Capirci C, Rubello D, Chierichetti F, Crepaldi G, Carpi A, Nicolini A, Mandoliti G, Polico C (2004) Restaging after neoadjuvant chemoradiotherapy for rectal adenocarcinoma: role of F18-FDG PET. Biomed Pharmacother 58:451–457

    CAS  PubMed  Google Scholar 

  • Chau I, Allen MJ, Cunningham D, Norman AR, Brown G, Ford HE, Tebbutt N, Tait D, Hill M, Ross PJ, Oates J (2004) The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol 22:1420–1429

    Article  CAS  PubMed  Google Scholar 

  • Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753–1759

    Article  PubMed  Google Scholar 

  • Dassen AE, Lips DJ, Hoekstra CJ, Pruijt JF, Bosscha K (2009) FDG-PET has no definite role in preoperative imaging in gastric cancer. Eur J Surg Oncol 35:449–455

    CAS  PubMed  Google Scholar 

  • Desch CE, Benson AB III, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, Minsky BD, Pfister DG, Virgo KS, Petrelli NJ (2005) Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 23:8512–8519

    Article  PubMed  Google Scholar 

  • Dimitrakopoulou-Strauss A, Strauss LG, Rudi J (2003) PET-FDG as predictor of therapy response in patients with colorectal carcinoma. Q J Nucl Med 47:8–13

    CAS  PubMed  Google Scholar 

  • Downey RJ, Akhurst T, Ilson D, Ginsberg R, Bains MS, Gonen M, Koong H, Gollub M, Minsky BD, Zakowski M, Turnbull A, Larson SM, Rusch V (2003) Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 21:428–432

    Article  PubMed  Google Scholar 

  • Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

    Article  CAS  PubMed  Google Scholar 

  • Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349:2241–2252

    Article  CAS  PubMed  Google Scholar 

  • Facey K, Bradbury I, Laking G, Payne E (2007) Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess 11:iii–iv, xi-267

    Google Scholar 

  • Figueredo A, Rumble RB, Maroun J, Earle CC, Cummings B, McLeod R, Zuraw L, Zwaal C (2003) Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer 3:26

    Article  PubMed  Google Scholar 

  • Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T, Pratt B, Husband J, Flower M, Ott R (1996) Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 14:700–708

    CAS  PubMed  Google Scholar 

  • Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, Dupont P, Bormans G, Hiele M, De Leyn P, Van Raemdonck D, Coosemans W, Ectors N, Haustermans K, Mortelmans L (2000) Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma [in process citation]. J Clin Oncol 18:3202–3210

    CAS  PubMed  Google Scholar 

  • Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman RE, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF (2008) Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 49:480–508

    Article  PubMed  Google Scholar 

  • Garcea G, Ong SL, Maddern GJ (2009) The current role of PET-CT in the characterization of hepatobiliary malignancies. HPB (Oxford) 11:4–17

    Google Scholar 

  • Gjedde A, Diemer NH (1983) Autoradiographic determination of regional brain glucose content. J Cereb Blood Flow Metab 3:303–310

    CAS  PubMed  Google Scholar 

  • Guillem JG, Moore HG, Akhurst T, Klimstra DS, Ruo L, Mazumdar M, Minsky BD, Saltz L, Wong WD, Larson S (2004) Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. J Am Coll Surg 199:1–7

    Article  PubMed  Google Scholar 

  • Halligan S, Altman DG, Taylor SA, Mallett S, Deeks JJ, Bartram CI, Atkin W (2005) CT colonography in the detection of colorectal polyps and cancer: systematic review, meta-analysis, and proposed minimum data set for study level reporting. Radiology 237:893–904

    Article  PubMed  Google Scholar 

  • Heinrich S, Goerres GW, Schafer M, Sagmeister M, Bauerfeind P, Pestalozzi BC, Hany TF, von Schulthess GK, Clavien PA (2005) Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 242:235–243

    Article  PubMed  Google Scholar 

  • Iannaccone R, Catalano C, Mangiapane F, Murakami T, Lamazza A, Fiori E, Schillaci A, Marin D, Nofroni I, Hori M, Passariello R (2005) Colorectal polyps: detection with low-dose multi-detector row helical CT colonography versus two sequential colonoscopies. Radiology 237:927–937

    Article  PubMed  Google Scholar 

  • Jeffery GM, Hickey BE, Hider P (2002) Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev CD002200

    Google Scholar 

  • Jensch S, Bipat S, Peringa J, de Vries AH, Heutinck A, Dekker E, Baak LC, Montauban van Swijndregt AD, Stoker J (2010) CT colonography with limited bowel preparation: prospective assessment of patient experience and preference in comparison to optical colonoscopy with cathartic bowel preparation. Eur Radiol 20;146–56

    Google Scholar 

  • Johnson CD, Chen MH, Toledano AY, Heiken JP, Dachman A, Kuo MD, Menias CO, Siewert B, Cheema JI, Obregon RG, Fidler JL, Zimmerman P, Horton KM, Coakley K, Iyer RB, Hara AK, Halvorsen RA Jr, Casola G, Yee J, Herman BA, Burgart LJ, Limburg PJ (2008) Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med 359:1207–1217

    Article  CAS  PubMed  Google Scholar 

  • Juweid ME, Cheson BD (2006) Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354:496–507

    Article  CAS  PubMed  Google Scholar 

  • Kato H, Miyazaki T, Nakajima M, Takita J, Kimura H, Faried A, Sohda M, Fukai Y, Masuda N, Fukuchi M, Manda R, Ojima H, Tsukada K, Kuwano H, Oriuchi N, Endo K (2005) The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer 103:148–156

    Article  PubMed  Google Scholar 

  • Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, Bredenkamp R, Hofler H, Fink U, Peschel C, Schwaiger M, Siewert JR (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8:797–805

    Article  PubMed  Google Scholar 

  • Lubezky N, Metser U, Geva R, Nakache R, Shmueli E, Klausner JM, Even-Sapir E, Figer A, Ben-Haim M (2007) The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg 11:472–478

    Article  PubMed  Google Scholar 

  • McAndrew MR, Saba AK (1999) Efficacy of routine preoperative computed tomography scans in colon cancer. Am Surg 65:205–208

    CAS  PubMed  Google Scholar 

  • Melton GB, Lavely WC, Jacene HA, Schulick RD, Choti MA, Wahl RL, Gearhart SL (2007) Efficacy of preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography for assessing primary rectal cancer response to neoadjuvant therapy. J Gastrointest Surg 11:961–969; discussion 969

    Google Scholar 

  • Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214

    Article  CAS  PubMed  Google Scholar 

  • Minn H, Zasadny KR, Quint LE, Wahl RL (1995) Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 196:167–173

    CAS  PubMed  Google Scholar 

  • Nagata K, Okawa T, Honma A, Endo S, Kudo SE, Yoshida H (2009) Full-laxative versus minimum-laxative fecal-tagging CT colonography using 64-detector row CT: prospective blinded comparison of diagnostic performance, tagging quality, and patient acceptance. Acad Radiol 16:780–789

    Article  PubMed  Google Scholar 

  • National Oncology PET Registry (NOPR) (2009) Cancers and indications eligible for entry in the NOPR. http://www.cancerpetregistryorg. Accessed 10 Aug 2009

  • Oda M, Kitasaka T, Mori K, Suenaga Y, Takayama T, Takabatake H, Mori M, Natori H, Nawano S (2009) Digital bowel cleansing free colonic polyp detection method for fecal tagging CT colonography. Acad Radiol 16:486–494

    Article  PubMed  Google Scholar 

  • Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, Fuchs M, Zimmermann A, John W, Von Hoff D, Arning M, Kindler HL (2005) A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16:1639–1645

    Article  CAS  PubMed  Google Scholar 

  • Okazumi S, Isono K, Enomoto K, Kikuchi T, Ozaki M, Yamamoto H, Hayashi H, Asano T, Ryu M (1992) Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med 33:333–339

    CAS  PubMed  Google Scholar 

  • Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R, Stein H, Lordick F, Link T, Schwaiger M, Siewert JR, Weber WA (2003) Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 21:4604–4610

    Article  CAS  PubMed  Google Scholar 

  • Ott K, Herrmann K, Krause BJ, Lordick F (2008) The value of PET imaging in patients with localized gastroesophageal cancer. Gastrointest Cancer Res 2:287–294

    PubMed  Google Scholar 

  • Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, Lee WJ, Kim CM, Nam BH (2008) A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 49:1912–1921

    Article  PubMed  Google Scholar 

  • Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttila I, Alhava E (1992) A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patients. Anticancer Res 12:2309–2314

    CAS  PubMed  Google Scholar 

  • Patlak CS, Blasberg RG, Fenstermacher JD (1983) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 3:1–7

    CAS  PubMed  Google Scholar 

  • Rappeport ED, Loft A, Berthelsen AK, von der Recke P, Larsen PN, Mogensen AM, Wettergren A, Rasmussen A, Hillingsoe J, Kirkegaard P, Thomsen C (2007) Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation. Acta Radiol 48:369–378

    Article  CAS  PubMed  Google Scholar 

  • Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O’Dwyer PJ (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505–2512

    Article  CAS  PubMed  Google Scholar 

  • Renehan AG, Egger M, Saunders MP, O’Dwyer ST (2002) Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 324:813

    Article  PubMed  Google Scholar 

  • Rex DK, Rahmani EY, Haseman JH, Lemmel GT, Kaster S, Buckley JS (1997) Relative sensitivity of colonoscopy and barium enema for detection of colorectal cancer in clinical practice. Gastroenterology 112:17–23

    Article  CAS  PubMed  Google Scholar 

  • Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:3776–3783

    Article  CAS  PubMed  Google Scholar 

  • Rockey DC, Koch J, Yee J, McQuaid KR, Halvorsen RA (2004) Prospective comparison of air-contrast barium enema and colonoscopy in patients with fecal occult blood: a pilot study. Gastrointest Endosc 60:953–958

    Article  PubMed  Google Scholar 

  • Rosman AS, Korsten MA (2007) Meta-analysis comparing CT colonography, air contrast barium enema, and colonoscopy. Am J Med 120(203–210):e204

    Google Scholar 

  • Ruers TJ, Wiering B, van der Sijp JR, Roumen RM, de Jong KP, Comans EF, Pruim J, Dekker HM, Krabbe PF, Oyen WJ (2009) Improved selection of patients for hepatic surgery of colorectal liver metastases with 18F-FDG PET: a randomized study. J Nucl Med 50:1036–1041

    Article  PubMed  Google Scholar 

  • Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA (2004) Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 240:1027–1034; discussion 1026–1035

    Google Scholar 

  • Sobhani I, Tiret E, Lebtahi R, Aparicio T, Itti E, Montravers F, Vaylet C, Rougier P, Andre T, Gornet JM, Cherqui D, Delbaldo C, Panis Y, Talbot JN, Meignan M, Le Guludec D (2008) Early detection of recurrence by (18)FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer 98:875–880

    Article  CAS  PubMed  Google Scholar 

  • Sperti C, Bissoli S, Pasquali C, Frison L, Liessi G, Chierichetti F, Pedrazzoli S (2007) 18-Fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 246:932–937; discussion 937–939

    Google Scholar 

  • Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, Schwaiger M, Fink U (2003) FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 30:288–295

    Article  CAS  PubMed  Google Scholar 

  • Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, Martens M, van den Borne B, Cole P, Sciot R, Dumez H, Silberman S, Mortelmans L, van Oosterom A (2003) 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39:2012–2020

    Article  CAS  PubMed  Google Scholar 

  • Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  CAS  PubMed  Google Scholar 

  • Therasse P, Eisenhauer EA, Buyse M (2006) Update in methodology and conduct of cancer clinical trials. Eur J Cancer 42:1322–1330

    Article  CAS  PubMed  Google Scholar 

  • Tohma T, Okazumi S, Makino H, Cho A, Mochiduki R, Shuto K, Kudo H, Matsubara K, Gunji H, Ochiai T (2005) Relationship between glucose transporter, hexokinase and FDG-PET in esophageal cancer. Hepatogastroenterology 52:486–490

    CAS  PubMed  Google Scholar 

  • van Westreenen HL, Westerterp M, Bossuyt PM, Pruim J, Sloof GW, van Lanschot JJ, Groen H, Plukker JT (2004) Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 22:3805–3812

    Article  PubMed  Google Scholar 

  • Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S–150S

    Article  CAS  PubMed  Google Scholar 

  • Warburg O (1956) On the origin of cancer cells. Science 123:309–314

    Article  CAS  PubMed  Google Scholar 

  • Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M (1999) Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 40:1771–1777

    CAS  PubMed  Google Scholar 

  • Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschlager G, Busch R, Siewert JR, Schwaiger M, Fink U (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19:3058–3065

    CAS  PubMed  Google Scholar 

  • Wieder HA, Brucher BL, Zimmermann F, Becker K, Lordick F, Beer A, Schwaiger M, Fink U, Siewert JR, Stein HJ, Weber WA (2004) Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22:900–908

    Article  CAS  PubMed  Google Scholar 

  • Wiering B, Krabbe PF, Jager GJ, Oyen WJ, Ruers TJ (2005) The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 104:2658–2670

    Article  PubMed  Google Scholar 

  • Yoshioka T, Yamaguchi K, Kubota K, Saginoya T, Yamazaki T, Ido T, Yamaura G, Takahashi H, Fukuda H, Kanamaru R (2003) Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med 44:690–699

    CAS  PubMed  Google Scholar 

  • Yuan S, Yu Y, Chao KS, Fu Z, Yin Y, Liu T, Chen S, Yang X, Yang G, Guo H, Yu J (2006) Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. J Nucl Med 47:1255–1259

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, USA

    Minsig Choi

  2. Karmanos Cancer Institute, Wayne State University School of Medicine, 4100 John R Street, HW04HO, Detroit, MI, 48201-2013, USA

    Anthony F. Shields

Authors
  1. Minsig Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anthony F. Shields
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anthony F. Shields .

Editor information

Editors and Affiliations

  1. Div. Medical Oncology, University of British Columbia, West 10th Avenue 600, Vancouver, V5Z 4E6, British Columbia, Canada

    Charles D. Blanke

  2. FB 19 Zentrum der Radiologie, Klinik f. Strahlentherapie, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, Frankfurt, 60590, Germany

    Claus Rödel

  3. Evanston Northwestern Healthcare, Northwestern University, Ridge Ave. 2650, Evanston, 60201, Illinois, USA

    Mark S. Talamonti

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Choi, M., Shields, A.F. (2011). Imaging in Gastrointestinal Cancer. In: Blanke, C., Rödel, C., Talamonti, M. (eds) Gastrointestinal Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-13306-0_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-13306-0_1

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-13305-3

  • Online ISBN: 978-3-642-13306-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation